<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001160</url>
  </required_header>
  <id_info>
    <org_study_id>770096</org_study_id>
    <secondary_id>77-DK-0096</secondary_id>
    <nct_id>NCT00001160</nct_id>
  </id_info>
  <brief_title>Studies on Tumors of the Thyroid</brief_title>
  <official_title>Studies on Thyroid Nodules and Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants in this study will be patients diagnosed with or suspected to have a thyroid&#xD;
      nodule or thyroid cancer.&#xD;
&#xD;
      The main purpose of this study is to further understand the methods for the diagnosis and&#xD;
      treatment of thyroid nodules and thyroid cancer. Many of the test performed are in the&#xD;
      context of standard medical care that is offered to all patients with thyroid nodules or&#xD;
      thyroid cancer. Other tests are performed for research purposes. In addition, blood and&#xD;
      tissue samples will be taken for research and genetic studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to gain knowledge and experience in the diagnosis and therapy of&#xD;
      thyroid cancer using established best standard of care and new techniques and approaches as&#xD;
      they are developed. Study subjects will include adults and children with thyroid nodules&#xD;
      requiring diagnostic imaging and fine needle aspiration biopsy, surgery, radioiodine scanning&#xD;
      or therapy, appropriate follow up, consisting of tumor markers monitoring and anatomical and&#xD;
      functional imaging. The limitations and significance of serum thyroglobulin (Tg) measurement&#xD;
      for diagnosing tumor recurrence will be assessed. The study will permit a continued&#xD;
      evaluation of the risk/benefit ratio of already established methods of administering&#xD;
      radioiodine therapy, including the impact of pre-treatment dosimetric calculations,&#xD;
      individualizing treatment with radioiodine. Under this protocol, samples of benign nodules&#xD;
      and cancer tissue specimens for research studies will be collected. Data and samples&#xD;
      collected during routine clinical care will be used to address research questions utilizing a&#xD;
      number of approaches including microscopy, immunohistochemistry, proteomics and molecular&#xD;
      analysis. All research studies will relate to the diagnosis, natural history and therapy of&#xD;
      thyroid tumors, regulation of thyroid function, and the effects of thyroid function on the&#xD;
      body. Blood and urine specimens will be collected for research studies in both the&#xD;
      hypothyroid and euthyroid state.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 1977</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of thyroid cancer</measure>
    <time_frame>As clinically indicated</time_frame>
    <description>Blood draws, CT and other scans, physical exams, surgery (if applicable), thyroid biopsy (if applicable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of thyroid disorders</measure>
    <time_frame>As clinically indicated</time_frame>
    <description>blood draws, CT and other scans, physical exam.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Hurthle Cell Thyroid Cancer</condition>
  <condition>Tall Cell Variant Thyroid Cancer</condition>
  <condition>Follicular Thyroid Cancer</condition>
  <condition>Thyroid Cancer</condition>
  <condition>Papillary Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>thyroid cancer</arm_group_label>
    <description>Patients with thyroid cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>thyroid nodules</arm_group_label>
    <description>Patients with thyroid nodules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68-Gallium Dotatate</intervention_name>
    <description>For evaluation risk/benefit evaluation</description>
    <arm_group_label>thyroid cancer</arm_group_label>
    <arm_group_label>thyroid nodules</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Only those with thyroid nodules and/or thyroid cancer will be allowed to enroll.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        In order to be eligible to participate in this study, an individual must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          1. Male or female, adults or children &gt;= 6 months+.&#xD;
&#xD;
          2. Patients with known or suspected thyroid nodules and/or thyroid cancer.&#xD;
&#xD;
          3. At risk family members of patients who have a genetic susceptibility to developing&#xD;
             thyroid cancer.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
        1. Serious underlying medical conditions that restrict diagnostic testing or therapy such&#xD;
        as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma&#xD;
        requiring intervention before thyroid cancer is addressed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Klubo-Gwiezdzinska, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Padmasree Veeraraghavan, N.P.</last_name>
    <phone>(301) 451-7710</phone>
    <email>padmasree.veeraraghavan@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joanna Klubo-Gwiezdzinska, M.D.</last_name>
    <phone>(301) 496-5052</phone>
    <email>joanna.klubo-gwiezdzinska@nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY dial 711</phone_ext>
      <email>ccopr@nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_1977-DK-0096.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Klubo-Gwiezdzinska J, Wartofsky L. The Role of Molecular Diagnostics in the Management of Indeterminate Thyroid Nodules. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3507-3510. doi: 10.1210/jc.2018-01081.</citation>
    <PMID>30032182</PMID>
  </reference>
  <reference>
    <citation>Thakur S, Tobey A, Daley B, Auh S, Walter M, Patel D, Nilubol N, Kebebew E, Patel A, Jensen K, Vasko V, Klubo-Gwiezdzinska J. Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III). Front Oncol. 2019 Sep 18;9:905. doi: 10.3389/fonc.2019.00905. eCollection 2019.</citation>
    <PMID>31620364</PMID>
  </reference>
  <verification_date>January 24, 2023</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>January 26, 2023</last_update_submitted>
  <last_update_submitted_qc>January 26, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroid Fine Needle Biopsy</keyword>
  <keyword>Radioiodine</keyword>
  <keyword>Dosimetry</keyword>
  <keyword>Natural History</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Adenocarcinoma, Follicular</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>.Subject level data will be shared upon request after appropriate collaboration agreements are in place.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

